THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
Silence Therapeutics Announces Intent to Submit Registration Statement to the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
20 May 2020
LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces it intends to confidentially submit a registration statement to the United States Securities and Exchange Commission (SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the Company's ordinary shares on the Nasdaq Stock Market (Nasdaq). The registration statement will be submitted to facilitate the creation of a trading market in the US for ADSs representing the Company's ordinary shares. The Company is not proposing to register any new issuance of securities. The registration statement will be subject to review by the SEC, and the proposed listing of ADSs representing the Company's ordinary shares is subject to approval by Nasdaq. The Company expects that its ordinary shares will continue to be admitted to trading on the AIM market of the London Stock Exchange.
For more information, please contact:
Silence Therapeutics plc
Iain Ross, Executive Chairman
Rob Quinn, Chief Financial Officer
Tel: +44 (0)20 3457 6900
Investec (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
Tel: +44 (0) 20 7597 5970
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
Tel: +44 (0) 20 3709 5700
Tel: +1 (443) 213-0505
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/
This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
The person who arranged for the release of this announcement on behalf of the Company was Rob Quinn, Chief Financial Officer.
Forward Looking Statements
Certain statements made in this announcement are forward-looking statements including with respect to the Company's intention to submit a registration statement to the U.S. Securities and Exchange Commission and the creation of a trading market for ADSs representing the Company's ordinary shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements including if the Company's registration statement is not declared effective by the SEC or if Nasdaq fails to approve the Company's ADS listing application. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.